Publication

Longitudinal DNA methylation profiling of the rectal mucosa identifies cell-specific signatures of disease status, severity and clinical outcomes in ulcerative colitis cell-specific DNA methylation signatures of UC

Downloadable Content

Persistent URL
Last modified
  • 06/25/2025
Type of Material
Authors
    Suresh Venkateswaran, Emory UniversityHari KK Somineni, Emory UniversityJason Matthews, Emory UniversityVarun Kilaru, Emory UniversityJeffrey S Hyams, Connecticut Children’s Medical CenterLee A Denson, Cincinnati Children’s Hospital Medical CenterRichard Kellamayer, Texas Childrens HospGregory Gibson, Emory UniversityDavid Cutler, Emory UniversityKaren Conneely, Emory UniversityAlicia Smith, Emory UniversitySubramaniam Kugathasan, Emory University
Language
  • English
Date
  • 2023-03-24
Publisher
  • BMC
Publication Version
Copyright Statement
  • © Crown 2023
License
Final Published Version (URL)
Title of Journal or Parent Work
Volume
  • 15
Issue
  • 1
Start Page
  • 50
End Page
  • 50
Grant/Funding Information
  • This research was supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH), under grant numbers R21DK119997 (SK) and 5U01DK095745 (LAD and JH).
  • This work was also supported by a research initiative grant (RISK) from the Crohn’s and Colitis Foundation, New York, NY.
Supplemental Material (URL)
Abstract
  • Background: In peripheral blood, DNA methylation (DNAm) patterns in inflammatory bowel disease patients reflect inflammatory status rather than disease status. Here, we examined DNAm in diseased rectal mucosa from ulcerative colitis (UC) patients, focusing on constituent cell types with the goal of identifying therapeutic targets for UC other than the immune system. We profiled DNAm of rectal mucosal biopsies of pediatric UC at diagnosis (n = 211) and non-IBD control (n = 85) patients and performed epigenome-wide association studies (EWAS) of specific cell types to understand DNAm changes in epithelial, immune and fibroblast cells across disease states, course, and clinical outcomes. We also examined longitudinal analysis on follow-up samples (n = 73), and comparisons were made among patients with clinical outcomes including those undergoing colectomy versus those who did not. Additionally, we included RNA-seq from the same subjects to assess the impact of CpG sites on the transcription of nearby genes during the disease course. Results: At diagnosis, UC rectal mucosa exhibited a lower proportion of epithelial cells and fibroblasts, and higher proportion of immune cells, in conjunction with variation in the DNAm pattern. While treatment had significant effects on the methylation signature of immune cells, its effects on fibroblasts and epithelial cells were attenuated. Individuals who required colectomy exhibited cell composition and DNAm patterns at follow-up more similar to disease onset than patients who did not require colectomy. Combining these results with gene expression profiles, we identify CpG sites whose methylation patterns are most consistent with a contribution to poor disease outcomes and could thus be potential therapeutic targets. Conclusions: Cell-specific epigenetic changes in the rectal mucosa in UC are associated with disease severity and outcome. Current therapeutics may more effectively target the immune than the epithelial and fibroblast compartments. Graphical abstract: [Figure not available: see fulltext.]
Author Notes
Keywords
Research Categories
  • Health Sciences, Obstetrics and Gynecology
  • Health Sciences, Nutrition

Tools

Relations

In Collection:

Items